Xanax metabolism depends heavily on CYP3A4. Strong inhibitors can increase levels 2-5x, causing severe sedation or respiratory depression.
With: Opioids (hydrocodone, oxycodone, morphine, fentanyl, etc.)
Risk: BLACK BOX WARNING: Severe respiratory depression, coma, death. Risk increases with dose and duration.
Action: AVOID unless absolutely necessary. If required, use lowest doses for shortest duration with close monitoring. Prescribe naloxone rescue kit. Counsel on overdose signs: unresponsiveness, slow breathing, blue lips.
With: Alcohol
Risk: Additive CNS depression: severe sedation, respiratory failure, amnesia, falls, death. Synergistic, not just additive.
Action: ABSOLUTE CONTRAINDICATION. Zero alcohol consumption. Even 1-2 drinks can be dangerous.
With: Strong CYP3A4 Inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin)
Risk: Alprazolam levels increase 2-5x. Severe sedation, prolonged effects, respiratory depression.
Action: CONTRAINDICATED per FDA labeling. If inhibitor unavoidable, reduce alprazolam by 50-75% or switch to lorazepam (not CYP-dependent).
With: Other CNS Depressants (barbiturates, sedating antihistamines, muscle relaxants, sleep aids)
Risk: Additive sedation, cognitive impairment, fall risk. Effects multiply, not add.
Action: Use extreme caution. Reduce doses of both. Monitor closely for excessive sedation. Consider non-sedating alternatives (e.g., cetirizine instead of diphenhydramine).
With: CYP3A4 Inducers (rifampin, carbamazepine, phenytoin, St. John's Wort)
Risk: Alprazolam levels decrease 50-70%. Loss of efficacy, breakthrough anxiety, withdrawal symptoms.
Action: Avoid if possible. If required, may need dose increase, but increases dependence risk. Consider alternative benzodiazepine or anxiolytic.
With: Grapefruit Juice
Risk: Moderate CYP3A4 inhibition. Alprazolam levels increase 20-40%.
Action: Avoid grapefruit juice and products. Effects can last 24+ hours.
With: Oral Contraceptives
Risk: May increase alprazolam levels by 20-30% (hormonal effect on CYP3A4).
Action: Monitor for increased sedation. May need dose reduction.
With: Smoking Cessation (varenicline, bupropion)
Risk: Smoking induces CYP1A2 (minor pathway). Quitting may increase levels slightly.
Action: Monitor for increased sedation during smoking cessation. May need dose reduction.